Login to Your Account

Financings Roundup

Sangart's Series G Adds $50M Now, $50M Later for MP4 Drugs

By Staff Reports

Wednesday, April 20, 2011
San Diego-based Sangart Inc. brought in more than $50 million in new equity funding to boost work on its MP4 pegylated hemoglobin platform in hemorrhage and sickle cell disease.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription